Yunnan Watson Biotechnology Co., Ltd. was established in 2001. After more than 20 years of development, it has now become a modern high-tech biopharmaceutical enterprise specializing in the research, development, production and sales of biotechnical drugs such as human vaccines. The company was listed on the Shenzhen Stock Exchange GEM in November 2010 (stock abbreviation: Watson Bio; stock code: 300142). The company is headquartered in Kunming, Yunnan, and has invested in and built a product R&D center located in Kunming National High-tech Zone, Shanghai Zhangjiang, and an industrialization base located in Yuxi National High-tech Zone, Yunnan. At the same time, vaccine industrialization technology innovation centers and industrialization bases are being built in Beijing, Guangdong, Chengdu and other places.

The company's main holding companies include: Yuxi Watson Biotechnology Co., Ltd., Shanghai Zerun Biotechnology Co., Ltd., Yuxi Zerun Biotechnology Co., Ltd., Beijing Watson Innovation Biotechnology Co., Ltd., Sichuan Watson Innovation Biotechnology Co., Ltd., Guangdong Watson Pharmaceutical Technology Co., Ltd., Guangzhou Watson Health Technology Co., Ltd., etc. Currently, the total number of employees exceeds 2,300. The company's core R&D and management teams of "combining Chinese and Western" are formed by entrepreneurial teams from major national biological research institutes and overseas returnees with a background in overseas biopharmaceutical giants.

The company has always adhered to the core driving force of development with technological innovation and continued to make high investments in independent research and development, and its R&D investment in operating income ranks among the top in the industry. The company and its subsidiaries are nationally recognized enterprise technology centers and national high-tech enterprises. It has successively undertaken 5 national "863" plans, undertaken 13 national "major new drug creation" special projects, and has 49 domestic authorized invention patents and 27 international PCT invention patents. After years of hard work and accumulation, the company now has two major global vaccine varieties: 13-valent pneumonia combined vaccine and HPV vaccine. Among them, the 13-valent pneumonia combination vaccine was successfully launched in April 2020, and the dual-valent HPV vaccine was approved in March 2022 and launched in May; all work on phase III clinical research of the 9-valent HPV vaccine is underway as planned. In the serum detection stage.

The company has always adhered to the belief that "life is priceless and technology is unlimited", established a complete quality management system, and continuously improved and improved the production process and product quality to ensure the quality of products and services. At present, there are 8 vaccine varieties (12 product specifications), and the company's non-immunization program vaccine has completed access to 31 provinces/cities across the country and exported to 18 countries overseas. The company's AC polysaccharide vaccine has been included in the national immunization program by the Egyptian government for five consecutive years since 2018; the 13-valent pneumonia combination vaccine was exported to Morocco in May 2022. This is the first overseas export since this vaccine was launched. It is also a milestone event in the internationalization of China's vaccine industry.

Watson Bio has always adhered to the principle of "making people born healthy" and integrated social responsibility into the company's development strategy and business management. Since 2018, the "People-friendly Project" has been launched in Kunming and Yuxi City. Elderly registered in the jurisdiction over 60 years old can receive the company's 23-valent pneumonia vaccine for free. Today, when the public is paying more and more attention to drug quality and safety, Watson Bio will continue to take it as its mission to strictly abide by product quality and safety, never forget its original aspiration, keep up with the pace of the times, and strive to create outstanding achievements worthy of society and the times.